Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.

Brian P EplingJoseph M RoccoKristin L BoswellElizabeth LaidlawFrances GalindoAnela KelloggSanchita DasAllison RoderElodie GhedinAllie KreitmanRobin L DewarSophie E M KellyHeather KalishTauseef RehmanJeroen HighbargerAdam RupertGregory KocherMichael R HolbrookAndrea LiscoMaura ManionRichard A KoupIrini Sereti

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Nirmatrelvir/ritonavir treatment does not impede adaptive immune responses to SARS-CoV-2. Clinical rebound corresponds to development of a robust antibody and T-cell immune response, arguing against a high risk of disease progression. The presence of infectious virus supports the need for isolation and assessment of longer treatment courses. Clinical trials registration. NCT04401436.

Keyphrases

immune response
sars cov
clinical trial
coronavirus disease
randomized controlled trial
dendritic cells
antiretroviral therapy
toll like receptor